Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Rapid Tests Preemptively Screen Drug Resistant Bacteria

By LabMedica International staff writers
Posted on 31 May 2012
Rapid diagnostic testing (RDT) can be used to screen carriers of suspected methicillin-resistant Staphylococcus aureus (MRSA) in hospitals. More...


Preemptive isolation of suspected MRSA carriers is a cornerstone of successful MRSA control policies but is hampered when using conventional cultures with diagnostic delays of three to five days, as many noncarriers remain unnecessarily isolated.

Scientists at the University Medical Center (Utrecht, The Netherlands) investigated whether RDT reduces the amount of unnecessary isolation days, the costs, and benefits in intensive care units (ICUs) in a multicenter hospital-wide study. The effects of RDT of MRSA was evaluated using polymerase chain reaction (PCR) assays added to screening with conventional microbiological culture methods for patients eligible for MRSA screening. Two real time PCR assays were subsequently evaluated: BD GeneOhm MRSA PCR between December 2005 and May 2007, and Xpert MRSA assay between April 2007 and June 2008.

A total of 163 patients at risk for MRSA carriage were screened and MRSA prevalence was 3.1%. Duration of isolation was 27.6 hours with BD GeneOhm MRSA PCR (previously known as IDI-MRSA, BD Diagnostics, San Diego, CA, USA) and 21.4 hours with GeneXpert (Cepheid, Sunnyvale, CA, USA), and would have been 96 hours when based on conventional cultures. The negative predictive value was 100% for both tests.

Numbers of isolation days were reduced by 44.3% with PCR-based screening at the additional costs of EUR 327.84 for the BD assay and EUR 252.14 for the GeneXpert test per patient screened. Costs per isolation day avoided were calculated to be EUR 136.04 for the BD assay and EUR 121.76 for the GeneXpert. The authors concluded therefore that in a low endemic setting for MRSA, RDT safely reduced the number of unnecessary isolation days.

The platforms used are not suited for the large volumes of multiple tests in a short period of time, as only 16 could be performed simultaneously on Cepheid's Smartcycler and four tests on the GeneXpert systems. This endorses the need for large volume testing or pooling of swabs in ICU patients to decrease unnecessary preemptive isolation time. Another option would be to use chromogenic agar-based screening, which has a slightly longer turn around time in the laboratory, but can be performed in large volumes and is easily implemented in routine laboratory practice, including weekends. The study was originally published on February 7, 2012, in the journal Critical Care.

Related Links:
University Medical Center Utrecht
BD Diagnostics
Cepheid


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Gold Member
Collection and Transport System
PurSafe Plus®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.